Search

Your search keyword '"Wanner C."' showing total 29 results

Search Constraints

Start Over You searched for: Author "Wanner C." Remove constraint Author: "Wanner C." Language undetermined Remove constraint Language: undetermined
29 results on '"Wanner C."'

Search Results

1. From WEDA to EDTA to ERA: 60 years of supporting European nephrology and counting

2. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

4. Quality of Life before and after the Start of Dialysis in Older Patients

5. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

6. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

7. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

9. Mediterranean diet as the diet of choice for patients with chronic kidney disease

10. Mediterranean diet as the diet of choice for patients with chronic kidney disease

11. Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial

12. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

13. Conference Participants. Iron management in chronic kidney disease: conclusions from a 'Kidney Disease: Improving Global Outcomes' (KDIGO) Controversies Conference

14. Numerical modeling of cold magmatic CO2 flux measurements for the exploration of hidden geothermal systems

16. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry

17. Fabry Registry. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy

18. Expert Working Group Report on nutrition in adult patients with renal insufficiency

19. Bone alkaline phosphatase and mortality in dialysis patients

21. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

26. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study

27. Sympathomodulatory effects of sodium–glucose transporter-2 inhibitors in the kidneys and beyond

28. Conservative Treatment of the Uremic Syndrome

29. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry

Catalog

Books, media, physical & digital resources